Cytokinetics begins patients enrollment for second cohort in phase IIb trial ... pharmabiz.com The primary objective of this trial is to evaluate the effect of 48 hours of intravenous omecamtiv mecarbil compared to placebo on dyspnea (shortness of breath) in patients with left ventricular systolic dysfunction hospitalized for acute heart failure ... |
